FDA Hears Mixed Message On Feasibility, Need For Orkambi Vs. Kalydeco Trial
Executive Summary
Some experts say a study in CF patients with the 508del mutation could not pass IRB muster, but others see an opportunity to answer the question of whether two drugs are needed or one will suffice.